Figure 6.
Dose-specific analysis highlighted specific reductions in IL-17, immune cells, and fibrosis only in the 200 mg once-daily belumosudil group. (A) Dose-group levels of collagen type I, CD3+ T, CD4+, IL-17+, CD3+CD4+ T, CD3+CD4− (CD8) T, and CD3− IL-17+ cells in the OM (n = 8) quantified by picrosirius red. (B) Dose-group levels of CD4+, CD3−CD4+, and myeloid cells (CD3−CD11b+) in labial MSGs (n = 6) via immunofluorescence staining. (C) Dose-group levels of IL-1RL1/ST2 in the saliva (n = 7) measured by enzyme-linked immunosorbent assay. P value <.05 is considered significant. Wilcoxon signed-rank test was performed. IL-1RL1/ST2, interleukin 1 receptor-like 1/suppression of tumorigenicity 2.

Dose-specific analysis highlighted specific reductions in IL-17, immune cells, and fibrosis only in the 200 mg once-daily belumosudil group. (A) Dose-group levels of collagen type I, CD3+ T, CD4+, IL-17+, CD3+CD4+ T, CD3+CD4− (CD8) T, and CD3− IL-17+ cells in the OM (n = 8) quantified by picrosirius red. (B) Dose-group levels of CD4+, CD3−CD4+, and myeloid cells (CD3−CD11b+) in labial MSGs (n = 6) via immunofluorescence staining. (C) Dose-group levels of IL-1RL1/ST2 in the saliva (n = 7) measured by enzyme-linked immunosorbent assay. P value <.05 is considered significant. Wilcoxon signed-rank test was performed. IL-1RL1/ST2, interleukin 1 receptor-like 1/suppression of tumorigenicity 2.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal